Publications by authors named "C Grancea"

Cytomegalovirus infections and reactivations are more frequent in people living with HIV (PLWH) and have been associated with increased risk of HIV progression and immunosenescence. We explored the impact of combination antiretroviral therapy (cART) on latent CMV infection in 225 young adults parenterally infected with HIV during childhood. Anti-CMV IgG antibodies were present in 93.

View Article and Find Full Text PDF

The objective of this study was to analyze the epidemiological links of the human immunodeficiency virus (HIV), hepatitis C virus (HCV) and HIV-HCV coinfections to less studied types of transmission in certain populations. We performed an observational, prospective study on 903 patients aged between 15-87 years who took part in the Open Test Project. They were divided in two subgroups: general population vs.

View Article and Find Full Text PDF

Immunosuppressed individuals, such as people living with HIV (PLWH), remain vulnerable to severe COVID-19. We analyzed the persistence of specific SARS-CoV-2 humoral and cellular immune responses in a retrospective, cross-sectional study in PLWH on antiretroviral therapy. Among 104 participants, 70.

View Article and Find Full Text PDF

The continuous variability of SARS-CoV-2 and the rapid waning of specific antibodies threatens the efficacy of COVID-19 vaccines. We aimed to evaluate antibody kinetics one year after SARS-CoV-2 vaccination with an mRNA vaccine in healthcare workers (HCW), with or without a booster. A marked decline in anti-Spike(S)/Receptor Binding Domain (RBD) antibody levels was registered during the first eight months post-vaccination, followed by a transitory increase after the booster.

View Article and Find Full Text PDF
Article Synopsis
  • Romania has a high prevalence of hepatitis B virus (HBV) in HIV patients, primarily affecting those parenterally infected in childhood; this study aimed to examine the genotypes and antiviral resistance in these co-infected individuals.
  • Among 117 patients studied, 73.5% had detectable HBV-DNA, with genotype A prevalent in long-term treatment patients and genotype D found mostly in recent injecting drug users; both genotypes showed resistance mutations.
  • The findings highlight significant differences in liver disease progression and treatment resistance between the two genotypes, underscoring the need for monitoring and targeted treatment strategies for co-infected patients.
View Article and Find Full Text PDF